‘We took Ravgen head-on’: How we won zero-damages and others didn't

Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

UPC hands Occlutech second win against Chinese medtech company in a month

US life sciences damages averaged $33.5m between 2019-2025

Quantum and photonics tech licensing expert joins EIP

Court upholds $83m sequencing verdict and sets royalty rate

Exclusive: ‘Cultural differences are an asset’ at the UPC

Amgen and subsidiary dealt $20m blow over rodent antibody tech

Ex-Simmons head of IP joins Carpmaels & Ransford

Moderna: BioNTech is claiming work ‘it never did’

‘We took Ravgen head-on’: How we won zero-damages and others didn't

More on this story

Editor's picks

Editor's picks

More features